Table 3

Combined outcome scores

StudyTreatment(s)ControlFollow-upParametersTreatment. mean (std)Control mean (std)Effect sizeMagnitude of effect
Panda (2014)26Curene (n=25)Placebo (n=25)Day 7VAS46.59 (8.19)51.94 (4.16)0.8Large
WOMAC total score34.88 (5.27)36.40 (3.88)0.3Small
Pain7.36 (1.73)8 (1.12)0.4Small
Stiffness4.16 (1.07)4.64 (0.91)0.5Moderate
PF23.36 (3.05)23.76 (2.73)0.1Small
Day 15VAS41.71 (9.35)49.28 (4.40)1.0Large
WOMAC total score31.44 (4.85)34.36 (3.79)0.7Moderate
Pain6.6 (1.66)7.64 (0.91)0.8Large
Stiffness3.52 (0.96)4.4 (0.87)1.0Large
PF21.32 (2.85)22.32 (2.94)0.4Small
Day 30VAS36.63 (8.85)46.77 (3.84)1.5Large
WOMAC total score25.84 (5.54)32.76 (3.88)1.5Large
Pain5.8 (1.80)7.32 (1.07)1.0Large
Stiffness2.84 (1.07)4 (0.91)1.2Large
PF17.2 (3.65)21.44 (3.03)1.3Large
Day 60VAS27.26 (11.95)44.83 (4.27)2.0Large
WOMAC total score18.44 (4.75)30.76 (4.84)2.6Large
Pain4.28 (1.54)6.96 (1.43)1.8Large
Stiffness2.12 (0.97)3.76 (1.09)1.6Large
PF12.04 (3.12)20.04 (3.77)2.3Large
Nakagawa (2014)27Theramicin (n=18)Placebo (n=23)8 weeksVASN/AN/AN/A
Madhu (2013)28NR-INF-02 (n=29)Placebo (n=29)21st dayVAS38.83 (21.36)53.83 (15.84)0.8Large
WOMAC36.67 (16.08)52.23 (9.63)1.17Large
CGIC3.73 (1.92)5.53 (0.97)1.18Large
42nd dayVAS19.48 (17.84)46.03 (20.84)1.37Large
WOMAC27.14 (16.13)47.90 (12.59)1.43Large
CGIC2.21 (1.80)4.72 (1.27)1.61Large
Belcaro (2010)29*Meriva (n=50)Placebo (n=50)8 monthsWOMAC subscale scoresN/AN/AN/AN/A
Shep
(2019)30
Curcumin (n=70)Diclofenac (n=69)Day 14VAS4.69 (0.79)4.58 (0.60)0.2Small
KOOS
Pain72.70 (4.89)73.69 (3.97)0.2Small
Symptoms61.58 (5.65)61.93 (5.47)0.1Small
Function in daily living77.67 (5.90)80.54 (6.10)0.5Moderate
Function in sport and recreation68.43 (5.81)71.88 (5.01)0.6Moderate
Quality of Life59.64 (6.08)59.15 (7.73)0.1Small
Day 28VAS2.20 (0.81)2.20 (0.61)0.0Null
KOOS
Pain88.77 (5.62)90.38 (3.61)0.3Small
Symptoms67.95 (5.86)69.13 (5.50)0.2Small
Function in daily living94.58 (6.58)92.63 (2.71)0.4Small
Function in sport and recreation89.14 (6.43)91.88 (4.38)0.5Moderate
Quality of Life73.57 (7.46)72.26 (8.61)0.2Small
Panahi (2010)31Curcuminoids (n=19)Placebo (n=21)6 weeksWOMAC global score25.0 (13.0)40.6 (12.6)1.2Large
WOMAC pain6.1 (2.9)9.4 (3.4)1.0Large
WOMAC stiffness0.15 (0.5)0.76 (0.9)0.8Large
*Henrotin (2019)32BCL high dose
(n=49)
Placebo
(n=45)
Month 1VASN/AN/A*0.4Small
KOOS global score and subscalesN/AN/A
Month 3VASN/AN/A*0.4Small
 BCL low dose Month 1
 Month 3
KOOS global score and subscales
VAS
KOOS global score and subscales
VAS
KOOS global score and subscales
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
*0.35
*0.4
 Small
 Small
Kuptniratsaikul
(2009)33
C.domestica (n=45)Ibuprofen (n=46)Week 6Pain
Level of walking2.7 (2.5)3.1 (2.3)0.2Small
Stairs3.1 (1.5)3.8 (2.4)0.4Moderate
Function
Time spent on 100 m walk96.7 (17.0)97.0 (25.7)0.0Null
Time spent on going up and down of flight of stairs24.8 (10.2)25.9 (12.3)0.1Small
Kuptniratsaikul
(2014)34
C.domestica
(n=171)
Ibuprofen
(n=160)
4 weeksWOMAC total score3.36 (2.04)3.23 (1.97)0.1Small
Pain3.25 (2.11)3.17 (1.98)0.0Null
Stiffness3.28 (2.38)3.16 (2.36)0.1Small
PF3.41 (2.09)3.26 (2.05)0.1Small
6 min walk (metres)345.43 (91.66)347.99 (86.60)0.0Null
Srivastava (2016)35CL extract (n=78)Placebo (n=82)Day 60VAS4.96 (0.07)6.00 (0.11)11Large
WOMAC
Pain11.19 (0.26)12.05 (0.21)3.6Large
Stiffness4.51 (0.21)4.70 (0.23)0.9Large
PF41.28 (0.51)45.11 (0.37)8.6Large
Day 120VAS4.03 (0.08)5.11 (0.14)9.5Large
WOMAC
Pain9.48 (0.17)10.16 (0.16)4.1Large
Stiffness4.08 (0.17)4.16 (0.18)0.5Moderate
PF32.14 (0.40)33.88 (0.50)3.8Large
  • BCL, bio-optimised Curcuma longa; CGIC, Clinician Global Impression Change; CL, Curcuma longa; KOOS, Knee injury Osteoarthritis Outcome Score; PF, Pain and Function; VAS, Visual Analogue Score; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.